Korea Institute of Science and Technology

Osong Medical Innovation Foundation, Korea University Research and Business Foundation

Seoul National University

Cellvertics Co., Ltd.

Hong Seog Seo

Jong Min Choi

Byung Hwa Jung

Yong Jik Lee

Ji Yong Park

Sungeun Kim

Jae Min Jeong

Hyeon Soo Kim

Youngsub Eom

Jong-Suk Song

Yun Sang Lee

Young Sub Eom

Eung Ju Kim

The present disclosure relates to a pharmaceutical composition for treating or preventing diabetic cataract, which contains midodrine or a pharmaceutically acceptable salt thereof as an active ingredient.

Pharmaceutical composition for treating or preventing diabetic cataract

A carrageenan derivative according to the present disclosure can quickly and easily detect and label the presence of inflammation-related macrophages and, particularly, can accurately and easily identify M1-type macrophages highly associated with early inflammation. In addition, the carrageenan derivative has advantages in that it can be produced easily, environmental pollution is minimized because a small amount of organic solvent is used, and initial cost is low.

Carrageenan derivative, probe for labelling macrophages, and method for preparing same

The present disclosure relates to a method and a diagnostic kit for diagnosing stable angina and acute myocardial infarction early through simple blood testing and checking of clinical parameters. Unlike conventional diagnostic methods, stable angina can be diagnosed as distinguished from acute myocardial infarction according to the present disclosure by using one diagnostic platform based on the change in the in-vivo levels of biological metabolites having different metabolic pathways and clinical parameters as well as medications affecting the onset and progress of the disease through multivariable analysis.

Kit for diagnosis of coronary heart disease using multi-metabolites and clinical parameters, and method for diagnosis of coronary heart disease using the same

The present disclosure provides a multi-metabolite platform using one or more metabolite selected from a group consisting of tryptophan, homoserine, fatty acid (16:1), fatty acid (18:0), fatty acid (18:1), fatty acid (18:2), fatty acid (22:6), phosphatidylcholine (PC) (34:2), PC (34:3), lysophosphatidylcholine (lysoPC) (16:0), lysoPC (18:0), lysoPC (20:3), lysoPC (20:4), lysoPC (22:6), monoglyceride (18:1/0:0/0:0) and sphingomyelin (d18:2/16:0) as a biomarker, which can diagnose acute coronary syndrome as well as the symptoms occurring prior to the onset of the disease simply and accurately through in-vivo level analysis.

Multi-metabolites platform for diagnosis of acute coronary syndrome

Growing community of inventors

Seoul, South Korea

Hong Seog Seo